Harel Insurance Investments & Financial Services Ltd. Purchases 834 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 73.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,972 shares of the biopharmaceutical company’s stock after acquiring an additional 834 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Regeneron Pharmaceuticals were worth $1,109,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $226,000. Exchange Traded Concepts LLC boosted its stake in Regeneron Pharmaceuticals by 17.5% during the second quarter. Exchange Traded Concepts LLC now owns 3,940 shares of the biopharmaceutical company’s stock worth $2,068,000 after acquiring an additional 588 shares in the last quarter. Diversified Trust Co grew its holdings in Regeneron Pharmaceuticals by 35.3% in the second quarter. Diversified Trust Co now owns 3,889 shares of the biopharmaceutical company’s stock worth $2,042,000 after purchasing an additional 1,015 shares during the period. Finally, CX Institutional increased its stake in Regeneron Pharmaceuticals by 7.9% in the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 22 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $733.04 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The firm has a market cap of $77.04 billion, a price-to-earnings ratio of 17.55, a PEG ratio of 1.92 and a beta of 0.39. The company has a fifty day moving average price of $748.87 and a 200-day moving average price of $637.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the firm posted $12.46 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 8,431 shares of company stock valued at $5,733,521. Insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on REGN shares. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Wells Fargo & Company raised their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Scotiabank boosted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $791.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.